Share Purchase by a Director

RNS Number : 4089S

ReNeuron Group plc

14 July 2022

 

ReNeuron Group plc

("ReNeuron" or "the Group")

Share Purchase by a Director

ReNeuron Group plc (AIM: RENE), a UK based leader in stem cell derived exosome technologies , announces that Catherine Isted, Chief Financial Officer, has purchased 50,000 ordinary shares of 1p each in the Company ("Ordinary Shares").

Name	Title	Number of Ordinary Shares purchased	Resulting beneficial interest in the Company's Ordinary Shares	Percentage of Company's Total Voting Rights
Catherine Isted	Chief Financial Officer	50,000	50,000	0.09%

  ENDS

Enquiries:

ReNeuron		www.reneuron.com/investors
Iain Ross, Chairman		Via Walbrook PR
Catherine Isted, Chief Financial Officer
Liberum Capital Limited (NOMAD and Joint Broker) Phil Walker (Investment Banking) Richard Lindley (Investment Banking) Ben Cryer (Investment Banking)		[phone]
Allenby Capital Limited (Joint Broker)		[phone]
James Reeve/George Payne (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations)		[phone] or [e-mail]
Paul McManus / Alice Woodings	[phone] / [phone]

About ReNeuron

ReNeuron is a UK based leader in proprietary stem cell derived exosome technologies, harnessing its unique stem cell technologies to develop 'off the shelf' treatments for diseases with significant unmet needs.

ReNeuron's stem cell derived proprietary exosome technology platform offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. The Group has a growing number of partner collaborations with Global Pharma, Biotech and academic partners in this fast-expanding area of scientific and commercial interest. ReNeuron also has the ability, through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, to make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

The Group has out-licenced its CTX Programme for stroke disability and hRPC programme in retinitis pigmentosa to Fosun in China and is looking to out-license both of these programmes in other territories.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them

(Disclosure in relation to ordinary shares purchased by Directors and PDMRs)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Catherine Isted
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	ReNeuron Group plc
b)	LEI	2138003TU12CQ5TZO137
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument  Identification code	Ordinary Shares 1p RENE - GB00BF5G6K95
b)	Nature of the transaction	Acquisition of ordinary shares
c)	Price(s) and volume(s)	Price(s)  Volume(s) 31.9p 50,000
d)	Aggregated information	£15,950.00
e)	Date of the transaction	13 July 2022
f)	Place of the transaction	London Stock Exchange AIM Market

 

END

 

 

DSHBRGDRXXBDGDX